Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial-Reference-Cited by-同舟云学术

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Published:2005-10 Issue:9493 Volume:366 Page:1279-1289
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Dormandy John A,Charbonnel Bernard,Eckland David JA,Erdmann Erland,Massi-Benedetti Massimo,Moules Ian K,Skene Allan M,Tan Meng H,Lefèbvre Pierre J,Murray Gordon D,Standl Eberhard,Wilcox Robert G,Wilhelmsen Lars,Betteridge John,Birkeland Kåre,Golay Alain,Heine Robert J,Korányi László,Laakso Markku,Mokáň Marián,Norkus Antanas,Pirags Valdis,Podar Toomas,Scheen André,Scherbaum Werner,Schernthaner Guntram,Schmitz Ole,Škrha Jan,Smith Ulf,Tatoň Jan

Publisher

Elsevier BV

Subject

General Medicine

Reference18 articles.

1. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study;Roper;BMJ,2001

2. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Interventional trial;Stamler;Diabetes Care,1993

3. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk);Khaw;BMJ,2001

4. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction;Haffner;N Engl J Med,1998

5. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial;Lancet,2003

Cited by 3624 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases;Metabolism;2024-10

2. Pleiotropic Effects of Peroxisome Proliferator-Activated Receptor Alpha and Gamma Agonists on Myocardial Damage: Molecular Mechanisms and Clinical Evidence—A Narrative Review;Cells;2024-09-05

3. Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines;BMC Medicine;2024-09-04

4. Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes;The Lancet Diabetes & Endocrinology;2024-09

5. Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study;Clinical Therapeutics;2024-09